PDF(Sci-hub)
Abstract：
BACKGROUND: Myrrh (Commiphora myrrha (Nees) Engl.) has a long history of traditional use as a herbal medicine for different purposes. In ancient traditional Persian manuscripts, it has been noted that myrrh may act as uterine stimulant and probably cause complete abortion. However, there is no evidence to verify this comment. Therefore, the current study was carried out to evaluate the efficacy and safety of Myrrh in the treatment of incomplete abortion.
METHODS: In a randomized double-blinded placebo controlled clinical trial, 80 patients with ultrasound-documented retained products of conception (RPOC) were assigned to receive capsules containing 500 mg of Myrrh oleo-gum-resin or a placebo three times a day for 2 weeks. The existence of the retained tissue and its size were evaluated by ultrasound examination at the beginning and end of the study.
RESULTS: After 2 weeks, the mean diameter of the RPOC in the Myrrh group was significantly reduced compared with the placebo group (P < 0.001). Meanwhile, the rate of successful complete abortion was 82.9% in the intervention group and 54.3% in the placebo group (P = 0.01). The patients in both groups reported no serious drug-related adverse effects.
CONCLUSIONS: This study shows that Myrrh is effective and safe in the resolution of the RPOC and may be considered as an alternative option for treatment of patients with incomplete abortion. However, further studies on active compounds isolated from myrrh and their uterine stimulant effects are needed.
BACKGROUND: This study was retrospectively registered at Iranian Registry of Clinical Trials (www.irct.ir) IRCT code: IRCT20140317017034N7.
METHODS: In a randomized double-blinded placebo controlled clinical trial, 80 patients with ultrasound-documented retained products of conception (RPOC) were assigned to receive capsules containing 500 mg of Myrrh oleo-gum-resin or a placebo three times a day for 2 weeks. The existence of the retained tissue and its size were evaluated by ultrasound examination at the beginning and end of the study.
RESULTS: After 2 weeks, the mean diameter of the RPOC in the Myrrh group was significantly reduced compared with the placebo group (P < 0.001). Meanwhile, the rate of successful complete abortion was 82.9% in the intervention group and 54.3% in the placebo group (P = 0.01). The patients in both groups reported no serious drug-related adverse effects.
CONCLUSIONS: This study shows that Myrrh is effective and safe in the resolution of the RPOC and may be considered as an alternative option for treatment of patients with incomplete abortion. However, further studies on active compounds isolated from myrrh and their uterine stimulant effects are needed.
BACKGROUND: This study was retrospectively registered at Iranian Registry of Clinical Trials (www.irct.ir) IRCT code: IRCT20140317017034N7.
摘要：
背景：没药（Commiphoramyrha（Nees）Engl。）在传统上作为草药用于不同目的方面有着悠久的历史。在古代传统的波斯手稿中，据指出，没药可能作为子宫兴奋剂，并可能导致完全流产。然而,没有证据证实这一评论。因此,本研究旨在评估没药治疗不完全性流产的有效性和安全性.
方法：在一项随机双盲安慰剂对照临床试验中，80例超声记录保留的受孕产品（RPOC）的患者被分配接受含有500mgMyrrholeo胶树脂或安慰剂的胶囊，每天三次，持续2周。在研究开始和结束时通过超声检查评估保留组织的存在及其大小。
结果：2周后，与安慰剂组相比,Myrrh组RPOC的平均直径显著减小(P<0.001).同时,干预组完全流产成功率为82.9%,安慰剂组为54.3%(P=0.01).两组患者均未报告严重的药物相关不良反应。
结论：这项研究表明，没药在解决RPOC方面是有效和安全的，可以被认为是治疗不完全流产患者的替代选择。然而,需要进一步研究从没药中分离出的活性化合物及其对子宫的刺激作用。
背景：这项研究在伊朗临床试验注册（www.irct.ir)IRCT代码:IRCT20140317017034N7。
方法：在一项随机双盲安慰剂对照临床试验中，80例超声记录保留的受孕产品（RPOC）的患者被分配接受含有500mgMyrrholeo胶树脂或安慰剂的胶囊，每天三次，持续2周。在研究开始和结束时通过超声检查评估保留组织的存在及其大小。
结果：2周后，与安慰剂组相比,Myrrh组RPOC的平均直径显著减小(P<0.001).同时,干预组完全流产成功率为82.9%,安慰剂组为54.3%(P=0.01).两组患者均未报告严重的药物相关不良反应。
结论：这项研究表明，没药在解决RPOC方面是有效和安全的，可以被认为是治疗不完全流产患者的替代选择。然而,需要进一步研究从没药中分离出的活性化合物及其对子宫的刺激作用。
背景：这项研究在伊朗临床试验注册（www.irct.ir)IRCT代码:IRCT20140317017034N7。
